New Brain Cancer Treatment Listed on PBS
Australia has listed the drug VORANIGO (vorasidenib) on the Pharmaceutical Benefits Scheme for patients with Grade 2 IDH-mutant glioma. This marks the first new treatment for this rare brain cancer in over two decades.
Why it matters
The PBS listing significantly improves access and affordability for patients suffering from a previously incurable and rare form of brain cancer.
VORANIGO(r) (vorasidenib) is available on the Pharmaceutical Benefits Scheme (PBS) for eligible patients living with Grade 2 IDH-mutant gliomai
This is the first new treatment option in more than 20 years to be approved and listed on the PBS for eligible Australians living with this rare, incurable brain cancer. 1
IDH-mutant glioma is the most common malignant primary brain tumour in adults under 50 years of age.ii
Servier Australia welcomes today's Government announcement that Australians living with Grade 2 IDH-mutant astrocytoma or oligodendroglioma - a rare, incurable brain cancer - will have access to the first new treatment in more than 20 years. From 1 August VORANIGO(r) (vorasidenib) will be listed on the Pharmaceutical Benefits Scheme (PBS) for adults and adolescents aged 12 years and older with a susceptible IDH1 or IDH2 mutation who have not previously received systemic anticancer therapy or radiotherapy and meet the PBS eligibility criteria.1,iii
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in